Table 2.
Characteristics of included studies (2).
| Study | Intervention | Number of patients (T/C) | Intervention period | Relevant outcomes | |
|---|---|---|---|---|---|
| T | C | ||||
| Zheng et al | AP+① | CC + HCG | 60 (27/33) | 3 mo | ② |
| Liu et al | AP+① | LE | 40 (20/20) | 3 mo | ②③④ |
| Zheng et al | AP+① | CC + HCG | 57 (27/30) | 3 mo | ②③⑤⑥⑧ |
| Mo et al | AP+① | CC | 60 (30/30) | 6 mo | ⑥ |
| He et al | EA+① | LE + HCG | 80 (40/40) | 3 mo | ③⑥ |
| Wu et al | AP+① | CC | 76 (38/38) | 3 mo | ⑤⑥⑦⑧ |
| Liu et al | AP+①+CC | CC | 80 (40/40) | 9 mo | ③⑥ |
| Huang | AP+① | CC + HCG | 80 (40/40) | 6 mo | ②③④ |
| Zhang | AP+① | CC | 94 (47/47) | 3 mo | ⑤⑥⑦ |
| Du et al | AP+①+CC | CC | 103 (51/52) | 3 mo | ②③④⑥ |
| Huang | AP+① | CC + HCG | 100 (50/50) | 3 mo | ②③⑤⑥ |
| Li | AP+① | CC + HCG | 140 (70/70) | 3 mo | ②③④ |
| Hu | AP+①+CC | CC | 55 (27/28) | 6 mo | ③⑤⑥ |
| Zhang | AP+① | LE | 90 (45/45) | 3 mo | ②⑦ |
| Zhang MH | AP+①+CC | CC | 80 (40/40) | 1 mo | ③④⑥⑦ |
| Liang | AP+① | CC | 90 (45/45) | 0.5 mo | ③⑤⑥⑧ |
| Tao | AP+①+LE | LE | 132 (72/60) | 6 mo | ⑤⑥ |
| Zhang LN | AP+①+CC | CC | 98 (49/49) | 3 mo | ②③④⑦ |
| Hou | AP+①+CC | CC | 110 (55/55) | 3 mo | ②④⑥⑦ |
| He et al | AP+① | CC + HCG | 120 (60/60) | 3 mo | ②③④⑥⑦ |
| Sun et al | AP+① | CC | 96 (48/48) | 6 mo | ② |
AP = acupuncture, C = control group, CC = clomiphene citrate, EA = electroacupuncture, HCG = human chorionic gonadotropin, LE = letrozole, T = treatment group.
①Chinese medicine formulas; ②efficacy rate; ③endometrial thickness; ④maximum follicle diameter; ⑤ovulation rate; ⑥pregnancy rate; ⑦sex hormone levels; ⑧frequency of adverse events.